The Federal Trade Commission and New York attorney general's argument that Quincy Biosciences LLC used weak data to support cognitive benefit claims for its Prevagen supplement was not strong enough to sway a federal judge against dismissing their complaint.
In a Sept. 28 order granting Quincy’s request to dismiss the complaint in the US District Court for...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?